Client News / 12.13.2011 / CYLENE FIRST IN CLASS AGENTS SHOW PROMISE IN HIGH RISK BLOOD CANCERS AT ASH

San Diego, December 13, 2011 Cylene Pharmaceuticals, Inc. announced today that two of its first-in-class agents, both inhibitors of newly-validated targets, have demonstrated encouraging activity in several preclinical models of high risk leukemias, cancers for which there are limited clinical treatment options. Dr. Ross Hannan of the Peter MacCallum Cancer Centre (PMCC), Melbourne, Australia, reported how CX-5461, a targeted inhibitor of RNA Polymerase I (Pol I), safely triggers the non-genotoxic activation of p53 and outperforms standard of care agents in models of MLL-rearranged Acute Myeloid Leukemias (AML),  a subset  of AML where there is a clear unmet medical need. Separately, Dr. Renee Prins M.D. and colleagues of the Division of Hematology and Medical Oncology, Oregon Health & Science University (OHSU), Portland, OR, reported that CX-4945, the first clinical stage inhibitor of CK2, demonstrated significant preclinical activity in patient samples of Chronic Lymphocytic Leukemia (CLL), including those with high risk features. The data presented at the 53ndAnnual Meeting of the American Society of Hematology (ASH), held on December 10-13 in San Diego, CA., highlight the value of Cylene’s approach to exploiting newly-validated targets and underscore that CK2 and Pol I inhibitors provide exciting new agents in the battle against difficult to treat blood cancers.

Read the Full Press Release

Client News / 11.29.2011 / MD ANDERSON STUDY SHOWS PEM MAY INDICATE IF CHEMOTHERAPY IS EFFECTIVE

Chicago, IL – November 29, 2011 – Presented yesterday at the RSNA 2011 annual meeting, researchers from The University of Texas MD Anderson Cancer Center showed that using Positron Emission Mammography (PEM) to measure PEM values (PUV) from baseline may indicate whether neoadjuvant chemotherapy is effective. PEM is positioned to benefit this patient population as it may help identify when a chemotherapeutic regimen is not working.  PEM also has the potential to play a role in initial staging of breast cancer in patients at high risk for multifocal or multicentric disease who desire breast conservation therapy as an alternative to breast MRI.

Read the Full Press Release

Client News / 11.28.2011 / ANSELL LIMITED ACQUIRES A MINORITY SHARE IN YULEX CORPORATION

Chandler, AZ, November 28, 2011 – Ansell Limited (ANN.AX), a global leader in protection solutions, today announced it has purchased a minority share of Yulex Corporation, a manufacturer of biopolymers derived from guayule.  The investment is not expected to have any material impact on Ansell’s earnings per share in Fiscal Years 2012 and 2013.

Read the Full Press Release

Client News / 11.23.2011 / King Fahad Specialist Hospital First to Offer PEM in Middle East

San Diego, CA – November 23, 2011 – King Fahad Specialist Hospital in Dammam, Saudi Arabia, part of the Ministry of Health, is the first to offer Positron Emission Mammography (PEM) in the Middle East.  PEM is the breast application of the Naviscan high-resolution PET scanner that shows the location as well as the metabolic phase of a lesion.  It is the only FDA-cleared 3D Molecular Breast Imaging (MBI) device on the market.

Read the Full Press Release

Client News / 11.18.2011 / Yulex Wins Green Innovator of the Year Award, Again

CHANDLER, Ariz.; November 18, 2011 – The Arizona Technology Council presented Yulex Corporation with the 2011 Green Innovator of the Year award at the Governor’s Celebration of Innovation gala on Nov. 17 in Phoenix. This marks the second time Yulex has won this award, the company was first recognized as the Green Innovator of the Year in 2009.

Read the Full Press Release

Client News / 11.03.2011 / Jubilant HollisterStier Allergy Launches Educational YouTube Channel

SPOKANE, Washington, November 3, 2011 – HollisterStier Allergy, a division of Jubilant HollisterStier, is expanding their offerings for the entire allergy community with the launch of an educational YouTube Channel, JHSAllergy.

Read the Full Press Release

Client News / 10.19.2011 / Instituto Nacional de Cancerología es primer centro en México que ofrece Mamografía de Emisión Positrónica

SAN DIEGO, California, 19 de octubre de 2011 /PRNewswire/ — El Instituto Nacional de Cancerología (INCan), uno de los centros oncológicos mejor equipados en Latinoamérica, es el primero en ofrecer Mamografía de Emisión Positrónica (PEM, por su sigla en inglés) a los habitantes de México.  La PEM es la aplicación para mamas del escáner PET de alta resolución de Naviscan que muestra la ubicación y también la fase metabólica de una lesión.  Es el único dispositivo de ofrece Imágenes moleculares de las mamas (MBI, por su sigla en inglés) tridimensionales en el mercado que cuenta con la aprobación de la FDA.

Read the Full Press Release

Client News / 10.19.2011 / National Institute of Cancer Is the First Center in Mexico to Offer Positron Emission Mammography

San Diego, CA – October 19, 2011 – The National Institute of Cancer (INCan), one of the best- equipped oncologic centers in Latin America, is the first to offer Positron Emission Mammography (PEM) to the residents of Mexico.  PEM is the breast application of the Naviscan high-resolution PET scanner that shows the location as well as the metabolic phase of a lesion.  It is the only FDA-cleared 3D Molecular Breast Imaging (MBI) device on the market.

Read the Full Press Release

Client News / 10.13.2011 / Cylene Advances Breakthrough p53 Activator Toward the Clinic

San Diego, Oct 13, 2011 – Cylene Pharmaceuticals, Inc. has advanced its targeted, non-genotoxic, activator of p53 for the treatment of leukemias, lymphomas and multiple myeloma through formal preclinical development, the Company announced today.  The small molecule, CX-5461, avoids the direct DNA damaging side-effects typically seen with current p53 activating drugs by selectively inhibiting the newly-validated RNA Polymerase I (Pol I) cancer target. Upon activation the p53 protein functions as a tumor suppressor by causing cancerous cells to self-destruct.  By targeting Pol I to activate p53 in blood cancers, Cylene’s first-in-class agent safely triggers the body’s natural cancer fighting capability to selectively kill tumor cells.

Read the Full Press Release

Client News / 08.30.2011 / Jubilant HollisterStier Allergy Launches ‘Allergy Industry Insights’ Educational Webinar Series

SPOKANE, Washington, August 30, 2011 – HollisterStier Allergy, a division of Jubilant HollisterStier, is expanding their educational offerings for customers with the launch of Allergy Industry Insights, a series of free webinars for the allergist community. The webinars will serve as educational tools allergists can use to stay on top of developing trends and more effectively manage their practices.

Read the Full Press Release
  • Sort by Year:
  • 2012
  • 2011